Capsular Contracture: Causes and Grades, Answered

Every implant is walled off by a natural scar capsule; contracture happens when that capsule thickens and tightens, and researchers link the shift to low-grade inflammation around the device.

A capsule of scar tissue forms around any implanted device — that part is normal physiology, not a complication. Capsular contracture is the point where the capsule stops being a thin lining and starts squeezing the implant, changing how the breast looks and feels.

Research most consistently points to chronic low-grade inflammation as the trigger — from a thin bacterial film on the implant surface, blood collecting around the device early on, or the body's own scar response running hotter than usual. None of these fully explains every case, which is why prevention protocols target several factors at once rather than a single cause.

Individual scar biology varies widely, so two patients with identical implants and identical surgeons can have different capsule outcomes. If your breast has started to feel firmer or look higher than before, consult a board-certified plastic surgeon and describe the timeline rather than self-diagnosing.

The Baker scale grades contracture from a soft, natural-feeling breast to one that is hard, distorted, and painful — and the grade is assigned by physical examination, not by a lab test.

Clinicians worldwide describe contracture with the Baker classification, a four-step scale built on how the breast feels and looks in the examination room. Knowing roughly how the grades work helps patients report changes accurately.

Grade I is a breast that looks and feels natural — the capsule exists but is not clinically noticeable. Grade II feels slightly firm while still looking normal, Grade III is visibly firm or distorted, and Grade IV adds pain or tenderness on top of hardness and distortion. Treatment discussions usually begin at Grade III.

Because grading rests on palpation, the same breast can be read a grade apart by different examiners, and firmness itself varies with tissue thickness from person to person. If you suspect your grade has moved, have it re-examined by a specialist experienced in revision surgery instead of tracking it alone.

The first clues are usually subtle — a breast that feels firmer than its pair, sits a little higher, or feels tight when lying on it — and they tend to appear gradually rather than overnight.

Contracture rarely announces itself with sudden pain. Most cases begin as a slow change in firmness or position that patients notice over weeks, which is exactly why routine self-checks and scheduled follow-ups matter after augmentation or reconstruction.

Watch for one breast becoming firmer to the touch, the implant seeming to ride higher on the chest, a rounder or more ball-like contour, tightness when hugging or lying face down, and any new discomfort around the implant edge. Any one of these alone can have benign explanations; the pattern over time is what matters.

How quickly signs progress differs from patient to patient, and softness itself is felt differently depending on tissue thickness. Rather than waiting to see whether the change settles, book a consultation with a board-certified plastic surgeon and bring notes on when each change started.

Yes — one-sided contracture is common, because the local conditions around each implant, from bleeding to bacterial exposure, are never perfectly mirrored between the two sides.

Patients are often surprised when only one breast hardens while the other stays soft for years. Clinically this is unremarkable: contracture is driven by what happens in each individual implant pocket, not by a whole-body switch that flips both sides at once.

Each pocket has its own history — slightly different bleeding during surgery, different bacterial exposure, different tissue thickness, sometimes a small unnoticed fluid collection on one side only. Any of these can tip one capsule toward thickening while the other stays quiet, so asymmetric onset says little about what will happen to the soft side.

Whether the unaffected side needs anything beyond observation varies case by case, and so does the revision plan for the hardened side. A specialist consultation with imaging of both breasts is the practical next step when one side changes — decisions about the healthy side should be made there, not assumed.

The evidence is mixed: displacement exercises are still prescribed by some surgeons for smooth implants, while others have dropped them, and no rigorous trial has settled the question.

Implant massage — more precisely, displacement exercise — was once near-universal advice after augmentation. Today practice has split, and the honest answer to whether it prevents contracture is that the data does not clearly say yes or no.

The theory is that keeping a smooth implant moving stops the capsule from tightening around one fixed position. Supporting studies are small and older, and the exercises are generally considered inappropriate for textured or anatomically shaped implants, where movement is the opposite of the goal. Timing also matters — starting too early can stress fresh incisions.

Whether displacement exercise fits your case depends on implant type, placement plane, and healing progress — all of which differ between individuals. Follow the protocol of the surgeon who placed your implants, and if you read conflicting advice online, bring it to your next consultation rather than switching routines on your own.

A patient who has formed one contracted capsule has already shown how their tissue responds to an implant — and unless the underlying drivers change, the same biology meets the new device.

Recurrence is the hardest part of treating contracture: simply swapping the implant without addressing why the first capsule tightened leaves the odds tilted toward a repeat. This is why revision planning focuses as much on the pocket and the protocol as on the new implant itself.

Strategies with support in the literature include removing rather than merely releasing the old capsule, creating a fresh pocket in a different tissue plane, minimizing implant contact during insertion, and sometimes adding an acellular dermal matrix as a barrier layer. Each aims at a suspected driver — residual bacterial film, an inflamed pocket lining, or repeated tissue trauma.

Even with a thorough protocol, individual scar biology varies and no technique removes the possibility of recurrence entirely. Ask a revision-focused specialist to walk you through which drivers apply to your case and what the plan changes compared with your first operation — that conversation is a better predictor than any statistic.

Rippling is a fold in the implant shell showing through the overlying tissue — the thinner the layer of skin, fat, and gland covering the implant, the less there is to hide it.

Almost every implant shell folds slightly under gravity and movement; whether anyone can see it is a question of coverage. That is why rippling shows disproportionately in slim patients with little breast tissue, and why it is most often noticed at the outer or lower edge of the breast when leaning forward.

Three factors set how visible folding becomes: the thickness of tissue over the implant, how fully the implant is filled (underfilled saline devices fold more than cohesive gel), and the placement plane — an implant under the muscle borrows extra coverage in the upper pole. Slim patients start with the least tissue, so the other two levers matter more for them.

Options discussed for visible rippling range from observation to fat grafting over the thin area or exchanging the implant type, and which is appropriate varies with each person's tissue and goals. Consult a board-certified plastic surgeon to have the area assessed before assuming a device problem — coverage, not the implant, is often the issue.

Usually not. Rippling is a normal mechanical behavior of a soft shell under thin coverage; a true device failure, such as a rupture, is a different finding confirmed by imaging.

Seeing waves on the breast surface understandably raises the fear that the implant has failed. The two issues sit in different categories: rippling is about how the implant sits and what covers it, while a defect means the device itself has lost integrity.

Rippling typically appears as fine, position-dependent waves — more visible when leaning forward, less when lying back — with the breast otherwise unchanged in size and feel. Signs that point toward a device problem instead include a sudden change in size or shape, new firmness, or discomfort, and the distinction is ultimately made with ultrasound or MRI, not by eye.

How much rippling shows — and how much it bothers a patient — varies with tissue thickness and body position, so there is no universal threshold for intervention. If new waves appear or existing ones change character, schedule an imaging review with a specialist rather than concluding on your own that the device has failed.

Often you would not — cohesive gel tends to stay in place after a shell tear, which is why silicone rupture is called silent and why regulators recommend periodic imaging rather than symptom-watching.

Modern silicone implants are filled with cohesive gel that holds its shape, so a tear in the shell frequently produces no change a patient can feel. The finding often surfaces incidentally on a scan done for another reason — hence the term silent rupture.

When symptoms do occur they are nonspecific — a change in breast shape or size, new firmness, lumps, or discomfort. Because feel alone is unreliable, the US FDA advises people with silicone implants to have ultrasound or MRI screening starting some years after placement and periodically thereafter, even when the breast seems entirely normal.

Screening intervals are tailored to implant age, symptoms, and prior findings, and recommendations differ between individuals. If you do not know when your last implant scan was — or have never had one — that is a concrete question to bring to a breast specialist at your next consultation.

Unlike silicone, a saline rupture is usually hard to miss: the salt water leaks out, the body absorbs it, and the breast visibly deflates over hours to days.

Saline implants are filled with sterile salt water inside a silicone shell. When that shell tears or the valve fails, the fluid escapes and is absorbed by the body the way an IV drip would be — so the main event is not the fluid itself but the change in the breast.

The affected breast loses volume and sits noticeably smaller or flatter than its pair, sometimes with loose-feeling skin or a wrinkled upper contour. The leaked saline is absorbed without known harm, and the empty shell simply stays in the pocket until it is removed. A slow valve leak can take longer to declare itself than a frank tear, which is why some deflations unfold over weeks rather than overnight.

How quickly the change shows, and how the removal or exchange is planned, varies with the leak pattern and each patient's tissue. If one breast has visibly shrunk, photograph the change, note when it started, and arrange a consultation with a board-certified plastic surgeon to confirm the diagnosis and discuss next steps.

Current evidence has not tied ruptured silicone gel to systemic disease, but leaked gel can cause local problems — soreness, lumps, capsule changes — which is why removal is usually advised once a rupture is confirmed.

Finding out an implant has ruptured raises an immediate question: is the gel now dangerous? The measured answer from regulators is that cohesive gel tends to stay within the scar capsule, and studies have not established a link to systemic illness — while local effects remain a real, practical concern.

Most ruptures are intracapsular — the gel stays inside the capsule the body built around the implant, often without symptoms. Less commonly, gel migrates beyond the capsule and can form firm nodules called granulomas or cause tenderness and shape change. Because gel is not absorbed the way saline is, the standard advice after a confirmed rupture is planned removal, with or without replacement, rather than indefinite observation.

How urgent the surgery is depends on symptoms, gel location, and individual health factors, so timelines differ from patient to patient. Rather than reading the finding as an emergency or ignoring it, take the imaging report to a specialist consultation and agree on a removal schedule that fits your case.

Ultrasound is an accepted first-line screening tool for silicone rupture — quick, radiation-free, and widely available — with MRI held in reserve for cases the scan cannot settle.

US regulators list ultrasound alongside MRI as an acceptable way to screen silicone implants for silent rupture. For many patients it is the practical starting point: no contrast, no enclosed scanner, and it can be done during a routine clinic visit.

On a good-quality scan, an intact implant shows a clean shell line, while rupture produces recognizable disruptions in and around that line. Accuracy, however, depends on the examiner's experience and on tissue conditions such as thick capsules or prior surgery. An unambiguous result can stand on its own; an uncertain one is usually followed by MRI, which remains the more sensitive study for gel that has moved beyond the capsule.

How often screening should be repeated varies with implant age, symptoms, and prior findings — recommendations are individualized rather than fixed. If you are unsure whether your next check should be ultrasound or MRI, put the question to a breast imaging specialist or your surgeon at a consultation instead of choosing a modality on your own.

MRI is the most sensitive imaging test for silicone rupture. It is used for scheduled screening years after surgery, and whenever an ultrasound result or a symptom leaves the question open.

For silicone implants, MRI sits at the top of the imaging ladder. Regulators recommend periodic screening starting a few years after placement even without symptoms, and clinicians order MRI directly when a rupture is suspected but not yet proven.

A dedicated breast MRI shows the implant shell, the gel inside it, and the tissue around the capsule in fine detail, which lets radiologists distinguish a collapsed shell floating in gel from an intact device — and spot gel that has escaped the capsule. The trade-offs are cost, scan time in an enclosed machine, and occasional ambiguous findings that still need surgical confirmation.

Whether MRI or ultrasound is the right next test — and how often to repeat it — differs by implant type, years since surgery, and individual findings. Bring your implant card and prior reports to a consultation with your surgeon or a breast specialist, and let the screening plan be set there.

A seroma in the first weeks after surgery is a familiar healing event. The same fluid appearing a year or more later is uncommon — and because its causes range from benign to serious, it always earns a workup.

Surgeons distinguish sharply between early and late seromas. Early fluid reflects the fresh surgical pocket settling down; a late seroma — swelling that appears long after everything had healed — has no such innocent default explanation, which is why guidelines treat it as a finding to investigate, not to watch.

Causes of late periprosthetic fluid include low-grade infection, trauma, an inflamed or double capsule, and — rarely, mostly with textured devices — BIA-ALCL, an uncommon lymphoma of the capsule fluid. The evaluation is straightforward: imaging to confirm the fluid, then aspiration with laboratory analysis of what is drawn. Most results point to benign causes, but the rare ones are exactly what the test exists to catch early.

How a late seroma is managed after analysis varies widely with the cause and the individual case — from simple drainage to capsule surgery. If one breast has swollen noticeably years after implant surgery, skip home remedies and book a specialist consultation promptly; the fluid itself is the diagnostic sample.

Both are fluid collecting around an implant, but a hematoma is blood — usually early, tense, and bruised — while a seroma is clear serum that tends to build more slowly and quietly.

Swelling after breast implant surgery has two classic fluid culprits, and telling them apart matters because the timelines and treatments differ. The distinction starts with what is in the pocket: blood in a hematoma, protein-rich serum in a seroma.

A hematoma usually declares itself within the first days after surgery: one breast becomes tight, swollen, more painful, and often discolored as a vessel keeps oozing into the pocket. Sizable ones are typically evacuated surgically, both for comfort and because retained blood is linked to later capsule problems. A seroma is slower and softer — a gradual swelling, often without pain, that may be observed, aspirated with a needle, or drained depending on size and timing.

How each is handled varies with the amount of fluid, when it appeared, and individual healing, so the same swelling can be managed differently in two patients. New or growing swelling after implant surgery — early or late — is a reason to consult your surgeon or a breast specialist rather than to wait it out.

Calcium deposits can build up in the scar capsule as it ages. They are usually a benign marker of an older capsule, but they can stiffen the breast and need careful reading on mammograms.

Like scar tissue elsewhere in the body, an implant capsule changes over the years — and one of those changes is calcification, where mineral deposits form within the capsule wall. Hearing the word on an imaging report sounds alarming, but context is everything.

Capsular calcification becomes more common the longer an implant has been in place, and it often travels together with a thickened or contracted capsule. On its own it is not a disease; the practical issues are two. A heavily calcified capsule can make the breast feel firm and, during revision surgery, is usually removed along with the implant. And on mammograms, capsule calcifications must be distinguished by the radiologist from calcification patterns that need follow-up for other reasons.

How much calcification matters varies with its extent, the state of the capsule, and each patient's revision plans. If a report mentions calcification around your implant, ask a specialist to walk you through the finding at a consultation — in most cases it changes the conversation about timing of revision, not the diagnosis.

A double capsule is two capsule layers with a space between them — one stuck to the implant, one lining the pocket. It has been reported mainly with certain textured implants and often surfaces only at revision surgery.

Normally the body builds a single capsule that lines the implant pocket. In a double capsule, a second layer forms around the implant itself, leaving a gap between the two where the device can slide and fluid can collect — a quiet anatomical quirk with practical consequences.

The leading explanation involves textured surfaces: tissue initially grips the texturing, then a shearing movement separates that adherent layer from the pocket wall, and each surface heals into its own capsule. Many double capsules cause no symptoms; others show up as an implant that moves oddly, sits differently, or as late fluid between the layers. Because the space is hidden, the finding is often confirmed only on imaging or at revision surgery.

Whether a double capsule needs surgery depends on symptoms, fluid, and the implant involved — management is individualized, and quiet cases may simply be documented. If your implant has started moving or sitting differently, describe the change at a specialist consultation; it is one of several capsule findings the examination is designed to sort out.

A round implant looks the same at any angle, so turning changes nothing. A teardrop implant has a top and a bottom — if it rotates inside the pocket, the breast shape rotates with it.

Anatomically shaped — teardrop — implants carry more volume in the lower pole to mimic natural breast slope. That asymmetry is their selling point and their vulnerability: the design only works while the implant stays in the orientation the surgeon placed it in.

Teardrop implants are made with textured surfaces so surrounding tissue can grip the shell, and surgeons fit the pocket snugly to the implant for the same reason. Rotation becomes likelier when the pocket is oversized, when fluid or a double capsule reduces that grip, or early on before tissue has adhered. The telltale sign is a change in breast shape — fullness shifting upward or sideways — rather than pain, and it may come and go if the implant swings back.

Correction ranges from manual repositioning in early cases to pocket revision or exchanging to a round implant, and the right choice differs by anatomy and timing — an individualized call. If your breast contour has visibly shifted, avoid trying to twist the implant back yourself and have the orientation checked at a specialist consultation.

A capsule is the organized membrane the body always builds around an implant. An adhesion is scar tissue binding surfaces that should glide past each other. Related biology, different structures, different problems.

Patients researching breast surgery meet both words and often use them interchangeably. Both are products of the same wound-healing machinery, but a capsule is an expected, structured response to an implant, while adhesions are scar bridges that form where healing tissues fused together.

Every implant gets a capsule — a thin, continuous lining around the device — and it only becomes a problem if it thickens and contracts. Adhesions have no such default role: they can tether skin to underlying muscle, distort a scar when the arm moves, or restrict how tissue planes glide after any operation. In implant surgery, the capsule is assessed as a structure of its own, while adhesions are more a question of scar management and mobility.

Whether a firm or tethered spot is capsule-related or an adhesion is not something touch alone can settle, and how each is treated varies by location and individual healing. If an area feels bound down or pulls with movement, point it out at a consultation with your surgeon — the distinction takes an examination, sometimes with imaging.

Infection around an implant mostly announces itself in the early weeks with redness, warmth, and pain; exposure means the device has become visible through thinned or opened tissue. Both call for prompt specialist care.

Because an implant has no blood supply, the body cannot clear bacteria from its surface the way it can from living tissue. That single fact explains why implant infection and its most visible endpoint, exposure, are managed more decisively than similar problems in surgery without a device.

Early infection typically shows as spreading redness, warmth, swelling, worsening pain, fever, or discharge near the incision, most often within weeks of surgery — though delayed infections can follow dental work or other bacteremia years later. Exposure happens when overlying tissue thins or an incision separates until the implant is visible; once the device meets the outside world, salvage becomes difficult and treatment usually means removal, a healing interval, and reinsertion later.

Between the clear-cut cases sits a gray zone — mild redness that responds to antibiotics, thinning skin that can be reinforced before exposure — and where a given case falls varies with timing, bacteria, and individual tissue. Any spreading redness, fever, or visible device edge is a same-week reason to consult your surgeon, not a watch-and-wait finding.

Animation deformity is the visible shift or distortion of a breast implant when the pectoral muscle contracts — a mechanical side of submuscular placement, ranging from a subtle flicker to a bothersome pull.

Placing an implant under the pectoral muscle buys extra soft-tissue coverage, but it also puts a working muscle directly on top of the device. Every push-up or firm hug contracts that muscle over the implant, and in some patients the result is visible movement known as animation deformity.

For many, the movement is minor — a brief upward or lateral shift during exercise that clothing hides. For others, especially athletes and people who train the chest heavily, the distortion is frequent and visible enough to bother them, sometimes with a pulling sensation. When correction is pursued, the usual discussion is converting the pocket to a plane above the muscle, weighing lost muscle coverage against freedom from animation.

How visible animation is — and whether it justifies revision — varies with muscle bulk, tissue thickness, and lifestyle, so the same finding can be trivial for one patient and disruptive for another. If the movement bothers you, film it during a chest contraction and review the clip at a consultation with a board-certified specialist.

Some patients report fatigue, joint pain, or brain fog they attribute to their implants. Research has not established a causal mechanism, yet regulators now require the reports to be disclosed before surgery — an honest picture of an unsettled question.

Breast implant illness, often shortened to BII, is not a formal diagnosis but a patient-coined label for a wide set of systemic symptoms reported by some people with implants. The discussion sits between two facts: studies have not confirmed a disease caused by implants, and the volume of patient reports has been substantial enough to change regulatory practice.

Reported symptoms — fatigue, joint and muscle pain, memory or concentration problems, rashes — are real to the people experiencing them but nonspecific, overlapping many other conditions, which is one reason studies struggle to isolate an implant effect. The US FDA now requires patient decision checklists that mention these symptom reports before implant surgery, and researchers continue to study explant outcomes: some patients describe improvement after removal, others no change.

How to weigh this unsettled evidence differs by individual — existing symptoms, anxiety about the device, and reasons for surgery all enter the calculation. If systemic symptoms concern you, whether before augmentation or years after, raise them at a consultation with a specialist and ask how the current evidence applies to your situation; ruling out other causes is part of that conversation.

En bloc removal takes the implant and its capsule out as one sealed unit. Widely requested online, it is technically demanding, not always feasible, and — outside specific indications — debated among surgeons.

The term comes from cancer surgery, where removing tissue as one uncut block prevents spillage. Applied to explant surgery, en bloc means the capsule is never opened while it is being dissected free — an impressive-sounding phrase that in practice describes a technique with real trade-offs, not a quality grade.

Keeping the capsule sealed makes clear sense when its contents should not touch surrounding tissue — a confirmed BIA-ALCL diagnosis is the textbook indication, and some surgeons extend the logic to ruptured silicone. For routine explants with intact implants, professional opinion is split: a capsule stuck to ribs or muscle may force larger incisions and riskier dissection to stay en bloc, while a total or partial capsulectomy done in pieces removes the same tissue with less collateral cost.

Whether en bloc is achievable — or worth its cost — varies with capsule thickness, location, and each patient's anatomy, so the honest answer is case-by-case. Rather than requesting the term, describe your goal at a consultation with a revision specialist and ask which removal extent fits your capsule and why.

Two patients with the same diagnosis — the same contracture grade, the same rupture finding — can have very different courses, because the diagnosis names the event, not the tissue, timing, and health it happened in.

Online communities are full of side-by-side stories: one person sailed through the same complication that sent another back to the operating room twice. Rather than someone exaggerating, this spread is what clinicians expect — a complication label compresses a very individual situation into a single word.

Behind the same label sit different inputs: how thick and healthy the overlying tissue is, how strongly that person's biology builds scar, how early the problem was caught, which implant and surgical plane were involved, and background factors such as smoking, medications, or radiation history. Each variable shifts the course a little; together they explain why published complication descriptions read as ranges rather than fixed scripts.

This is why borrowing another patient's timeline — or their treatment decision — rarely transfers cleanly to your own case, however similar the diagnosis sounds. Treat community accounts as questions to bring to a specialist consultation, where the variables above can be read from your examination rather than assumed, and expect your plan to reflect individual factors more than the label.

Regulators are explicit that implants are not lifetime devices: the chance of rupture and other problems rises the longer an implant stays in the body — though there is no fixed expiry date that forces replacement.

A silicone shell flexing with every movement for years is a mechanical part, and mechanical parts fatigue. That is the plain reasoning behind the official phrase "breast implants are not lifetime devices" — not a countdown to a mandatory swap, but a reminder that the risk curve slopes upward with time.

With years in the body, the shell can weaken at fold lines, the capsule can thicken or calcify, and the cumulative chance of rupture, contracture, or position change grows. Yet an old implant that images clean and feels normal does not require removal on age alone — the widely repeated ten-year replacement rule is a rough planning heuristic, not a regulation. What regulators do ask of long-term implant holders is continued monitoring rather than calendar-driven surgery.

How fast an individual implant ages varies with the device generation, placement, and the body around it, so two implants of the same vintage can be in very different condition. If your implants are past their first decade, a sensible move is a consultation with a breast specialist to set up an imaging schedule — and to decide on facts, not on the anniversary.

Texturing was developed partly to disrupt the way capsules tighten, and some studies found lower contracture rates in certain placements — but the picture depends on where the implant sits, and texture carries its own separate discussions.

Smooth or textured is one of the oldest forks in implant design, and contracture sits at the center of the debate. The idea behind texturing is mechanical: a rough surface lets tissue grow into irregular contact, interrupting the uniform, shrinking scar shell that defines contracture.

The clearest signal in the literature concerns placement above the muscle, where several comparisons found less contracture with textured surfaces; under the muscle, the difference largely fades, which is one reason smooth implants placed submuscularly remain a standard combination. The texture story later grew more complicated when heavily textured devices were linked to BIA-ALCL and some were withdrawn from markets — so today the surface choice weighs contracture data against considerations that have nothing to do with contracture.

How much surface type matters for you depends on the planned pocket, your tissue, and which devices are available in your market — inputs that differ for every patient. Bring the smooth-versus-textured question to a consultation with a board-certified specialist and ask how it interacts with your placement plan, rather than treating either surface as the safer answer in the abstract.